Rocket Lab Corp
$37.45B- Market cap
- $38.46B
- Debt
- +$1.72M
- Cash
- −$1.02B
Capital structure 100% equity / 0% debt · EV / Revenue 62.23x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $38.46B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: RKLB stock price at premium vs BNTX $64.28 current versus $7.86 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BNTX's multiple
Implied fair value · at RKLB's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RKLB FY 2025 (ended Dec 31, 2025) · BNTX FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 62.23x
Capital structure 91% equity / 9% debt · EV / Revenue 6.08x
RKLB carries the larger enterprise value at $37.45B against $20.27B; BNTX trades on the lower EV / Revenue multiple (6.08x vs 62.23x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Rocket Lab Corp · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.00x
—
Net debt / EBITDA
Leverage against operating earnings
6.55x
4.45x
Cash and equivalents
Liquid reserves on the balance sheet
$1.02B
$7.68B
Total debt
Interest-bearing obligations outstanding
$1.72M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NORTHROP GRUMMAN CORP /DE/
RKLB vs NOC
BOEING CO
RKLB vs BA
LOCKHEED MARTIN CORP
RKLB vs LMT
L3HARRIS TECHNOLOGIES, INC. /DE/
RKLB vs LHX
Virgin Galactic Holdings, Inc
RKLB vs SPCE
Moderna, Inc.
RKLB vs MRNA
GILEAD SCIENCES, INC.
RKLB vs GILD
AMGEN INC
RKLB vs AMGN
REGENERON PHARMACEUTICALS, INC.
RKLB vs REGN
INCYTE CORP
RKLB vs INCY
VERTEX PHARMACEUTICALS INC / MA
RKLB vs VRTX
$2.68B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.